Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Pharmacokinetics (PK) Study in Lice Infested Children 6 Months to 3 Years of Age

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Topaz Pharmaceuticals Inc
ClinicalTrials.gov Identifier:
NCT00988533
First received: October 1, 2009
Last updated: March 30, 2012
Last verified: March 2012

October 1, 2009
March 30, 2012
September 2009
November 2009   (final data collection date for primary outcome measure)
  • Mean Plasma Concentration of Ivermectin in Samples Collected Before Application and at Specified Post-Application Time Points [ Time Frame: Before; 0.5, 1, 6, 24 hours and Up to 14 days post-application ] [ Designated as safety issue: No ]
    Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods with a sensitivity of 0.05 ng/mL before application and on Day 1 (0.5, 1, and 6 hours), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).
  • Summary of Pharmacokinetic Parameters Following Ivermectin Application. [ Time Frame: Before; 0.5, 1, 6, 24 hours, Day 8 and Day 15 post-application ] [ Designated as safety issue: No ]
    Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods before application and on Day 1 (0.5, 1, and 6 hours post-application), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).
  • Summary of Pharmacokinetic Parameter (Mean Concentration) Following Ivermectin Application. [ Time Frame: Before; 0.5, 1, 6, 24 hours, Day 8 and Day 15 post-application ] [ Designated as safety issue: No ]
    Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods before application and on Day 1 (0.5, 1, and 6 hours post-application), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).
  • Summary of Pharmacokinetic Parameter (Time of Observed Maximum Plasma Concentration) Following Ivermectin Application. [ Time Frame: Before; 0.5, 1, 6, 24 hours, Day 8 and Day 15 post-application ] [ Designated as safety issue: No ]
    Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods before application and on Day 1 (0.5, 1, and 6 hours post-application), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).
Assessment of bioavailability [ Time Frame: 15 days ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00988533 on ClinicalTrials.gov Archive Site
  • Number of Participants Reporting Adverse Events Following Ivermectin Treatment [ Time Frame: Day 1 up Day 28 post-application ] [ Designated as safety issue: No ]
    Adverse events were assessed at each visit and during the follow up phone call on Day 28.
  • Percentage of Participants Who Were Lice-Free by Visit Post-treatment With Ivermectin. [ Time Frame: Day 2, Day 8 and Day 15 post-application ] [ Designated as safety issue: No ]
    Eradication of live lice was assessed by visual examination of the scalp and hair.
  • Percentage of Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 8 and Day 15 Post-treatment With Ivermectin. [ Time Frame: Day 2, Day 8 and Day 15 post-application ] [ Designated as safety issue: No ]
    Eradication of live lice was assessed by visual examination of the scalp and hair before and following application of Ivermectin.
  • Liver Function Test Results at Before (Day 1) and Following Ivermectin Application on Days 2, 8, and 15 Post-application [ Time Frame: Day 1, Day 2, Day 8 and Day 15 post-application ] [ Designated as safety issue: No ]
    Liver function tests (Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, and Lactate Dehydrogenase) were performed before Ivermectin application on Day 1 (baseline) and on Days 2, 8, and 15 after application.
  • Liver Function Test Results at Before (Baseline) and Following Ivermectin Application on Days 2, 8, and 15 Post-application [ Time Frame: Day 1, Day 2, Day 8 and Day 15 post-application ] [ Designated as safety issue: No ]
    Liver function test (total bilirubin) was performed before treatment Day 1 (baseline) and following Ivermectin application on Days 2, 8, and 15 Post-application, respectively.
Efficacy as measured by absence of live lice [ Time Frame: 15 days ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Pharmacokinetics (PK) Study in Lice Infested Children 6 Months to 3 Years of Age
An Open-label Study to Assess the Bioavailability, Safety, Local Tolerance, and Efficacy of 0.5% Ivermectin Cream in Subjects 6 Months to 3 Years of Age With Pediculus Humanus Capitis (Head Lice) Infestation

The purpose of this study is to determine the bioavailability of 0.5% ivermectin cream in a pediatric population aged 6 months to 3 years.

Not Provided
Interventional
Phase 1
Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Head Lice
Drug: 0.5% Ivermectin Cream
Topical 0.5% ivermectin cream applied to scalp and hair on day 1
Experimental: 0.5% Ivermectin Cream
Intervention: Drug: 0.5% Ivermectin Cream
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
November 2009
November 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject must be 6 months to 3 years of age, inclusive, when informed consent is signed.
  • Subject must be infested with head lice as demonstrated by the presence of at least 1 live louse prior to treatment.
  • Subject is in general good health.
  • Subject's parent/guardian (caregiver) must be willing and able to bring subject to all study visits as scheduled.
  • Subject's caregiver must have provided written informed consent (assent is not required due to the young age of the subjects).
  • Subject's caregiver must agree to comply with the following study restrictions:

    • will not use any other form of lice treatment (eg, commercial, community/anecdotal, or mechanical/manual) on the subject for the duration of the study, unless directed to do so by study personnel.
    • will not shampoo, wash, or rinse the subject's hair or scalp until the Day 2 treatment evaluation has been completed.
    • will not cut or chemically treat subject's hair in the period between screening and follow-up on Day 15.
    • will use only study-provided shampoo on the subject for the duration of the study.
    • will follow all study instructions.

Exclusion Criteria:

  • Subjects who have received any OTC or prescription treatment for head lice in the last 2 weeks.
  • Subjects or subjects' caregivers who are unable to comply with the study obligations and all study visits.
  • Subjects whose caregivers do not understand the requirements for participation and/or may be likely to exhibit poor compliance, in the opinion of the Investigator.
  • Subjects with eczema, atopic dermatitis, or other chronic conditions of the scalp and skin.
  • Subjects with visible skin/scalp condition(s) that are not attributable to head lice infestation, such as an erythema score that is > 2, blisters, or any other condition that, in the opinion of the investigative personnel or Sponsor, would interfere with the PK, safety and/or efficacy evaluations.
  • Subjects with a history of allergy to ivermectin or any ingredients commonly included in hair products such as shampoos, hair conditioners, or styling aids.
  • Subjects with other diagnoses that, in the opinion of the Investigator, would interfere with the PK, safety, and/or efficacy assessments or would preclude study participation.
  • Subjects who have been treated with a systemic antibiotic within 2 weeks before screening.
  • Subject currently taking warfarin sodium (Coumadin®) or has taken within 2 weeks before screening.
  • Subjects who have been enrolled in any clinical study within the past 30 days; subjects may not participate in another study while participating in this study.
Both
6 Months to 3 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00988533
TOP008
No
Topaz Pharmaceuticals Inc
Topaz Pharmaceuticals Inc
Not Provided
Study Director: Medical Director Sanofi Topaz
Topaz Pharmaceuticals Inc
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP